- How mental health chatbots are trained on therapy sessionsAs people increasingly turn to AI for everyday tasks, companionship and emotional assurance, virtual mental health companies once wary of AI are racing to build out their own chatbots to stay compe…Endpoints · 24d ago↗ source
- Unicycive gets second CRL for kidney drug as manufacturing woes continueUnicycive Therapeutics’ chronic kidney disease drug was rejected by the FDA for a second time over persistent issues at a third-party contract manufacturer. The company’s phosphate binder drug ox…Endpoints · 24d ago↗ source
- Sanofi’s Lumizyme successor passes Phase 3 test in babies with Pompe diseaseSanofi said its enzyme replacement therapy succeeded in a registrational trial in a severe form of Pompe disease, paving the way for a key label expansion in the US. The French pharma is looking…